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Soon, the genetic basis of most human Mendelian diseases will be solved. The next challenge will
be to leverage this information to uncover basicmechanisms of disease and develop new therapies.
To understand how this transformation is already beginning to unfold, we focus on the ciliopathies,
a class of multi-organ diseases caused by disruption of the primary cilium. Through a convergence
of data involving mutant gene discovery, proteomics, and cell biology, more than a dozen pheno-
typically distinguishable conditions are now united as ciliopathies. Sitting at the interface between
simple and complex genetic conditions, these diseases provide clues to the future direction of
human genetics.Until a few years ago, identifying the genetic basis of an inherited
human disease was an arduous undertaking, requiring poten-
tially a decade or more of work in ascertainment of families
for linkage analysis, followed by endless fine mapping of the
locus and, finally, sequencing of candidate genes one by one
until that ‘‘eureka’’ moment when the likely causative gene was
identified. The newly discovered disease gene was often entirely
novel, without recognizable domains or a path to understand
the disease mechanism. A mouse model was then generated,
in which the disease gene was inactivated. The mouse faithfully
recapitulated the human phenotype in some cases but, more
often, showed no phenotype or phenotypes not clearly related
to the human disease. Once established, the model was studied
from multiple perspectives to understand the cell biological and
biochemical basis of disease, culminating in attempts to test
potential therapies. Although successful in a few instances
such as losartan treatment for Marfan syndrome (Habashi
et al., 2006), this path has not fulfilled the promises of genomic
medicine.
This strategy has begun to change over the past 10 years due
to increased knowledge of human genetic diseases, annotation
of the human genome, and an amazing suite of tools to explore
disease mechanisms. It is not uncommon now to open up
a journal to find that geneticists have solved the molecular
basis of a dozen or more conditions. And since we now know
a lot more about the function of genes, protein domains, and
networks, frequently just the discovery of the molecular cause
of a disease can partially explain its mechanism. For instance,
the discovery that the Rett syndrome gene encodes a methyl-
CpG-binding protein (Amir et al., 1999) immediately set the stage
for a host of important discoveries in epigenetics related to brain
function. The types of mutations displayed by patients, known as
allelic diversity (Figure 1), can tell us something about the effect
of these disease-causing variants on protein function. By identi-
fying patients with different phenotypes due to specific types of70 Cell 147, September 30, 2011 ª2011 Elsevier Inc.mutations in the same gene (i.e., genocopies), we can under-
stand human disease as a network of related signs and symp-
toms. For example, specific types of mutations in the gene
encoding p53 predispose to very different types of cancers. By
comparing the genes mutated in phenotypically related human
diseases, we can learn about the disturbed protein networks
that underlie them. Finally, by exploring gene-gene and gene-
environment interactions, we can begin to characterize genetic
and epigenetic modifiers of disease. Perhaps the best example
is age-related macular degeneration, in which a substantial
part of the risk of disease can be quantified based on gene-envi-
ronment interactions (Chen et al., 2010).
The Ciliopathies: One Organelle, Many Disorders
Although they are individually rare conditions, the ciliopathies
have emerged as a dynamic new field of biology that exemplifies
how genetics can be employed to drive research in basic cell
biology and vice versa. The primary cilium is structured with
a basal body at its base and a 9-paired microtubule axoneme,
surrounded by plasma membrane but lacking the central pair
of microtubules and outer dynein arms that define its cousin,
the motile cilium. Primary cilia were first observed more than
a century ago and were initially thought to be evolutionary
remnants. How is it that biologists missed their importance for
so long?
More than a dozen disorders are now considered to be within
the ciliopathy spectrum, including Joubert syndrome (JBTS),
nephronophthisis (NPHP), Senior-Loken syndrome (SLS), orofa-
ciodigital (OFD), Jeune syndrome, autosomal dominant and
recessive polycystic kidney disease (ADPKD and ARPKD),
Leber congenital amaurosis (LCA), Meckel-Gruber syndrome
(MKS), Bardet-Biedl syndrome (BBS), Usher syndrome (US),
and some forms of retinal dystrophy (RD). Between them, these
conditions involve nearly every major body organ, including
kidney, brain, limb, retina, liver, and bone (Figure 2A), highlighting
Figure 1. Human Genetic Interactions in the
Ciliopathy Spectrum
Diseased individuals are in color, with severity
represented by darker shading. ‘‘Phenocopies’’
refers to the finding that patients with homozygous
or compound heterozygous mutations in two
different genes (i.e., AHI1 or INPP5E) can show
indistinguishable JBTS phenotypes. Multiple
allelism at the same locus indicates that mutations
in a single gene (i.e., CEP290) can lead to
various distinguishable phenotypes. ‘‘Modifiers’’
refers to evidence that potentially deleterious
sequence changes in a gene like AHI1 can
modify in quantifiable ways the phenotype
observed in patients with NPHP1 mutations.
(Black) Normal chromosome; (red) mutant chro-
mosome. AHI1, abelson helper integration site 1;
INPP5E, inositol polyphosphate-5-phosphatase E;
CEP290, centrosomal protein 290 kDa; NPHP1,
nephrocystin 1. BBS, Bardet-Biedl syndrome;
JBTS, Joubert syndrome; LCA, Leber congenital
amaurosis; MKS, Meckel syndrome; NPHP, neph-
ronophthisis; RD, retinal dystrophy; SLS, Senior
Loken syndrome.the important role of the primary cilium in development and
homeostasis. These conditions were largely defined by clinical
geneticists in the middle of the last century, who did their best
to ascribe syndromes to unique combinations of clinical features.
Individual diseases are known for the most commonly involved
or diseased organ: BBS patients display the triad of obesity,
polydactyly, and retinopathy but can display a host of other
pathologies. MKS is a lethal condition at birth, with occipital
encephalocele, PKD, and polydactyly. JBTS is characterized
by a very peculiar radiographic finding known as the ‘‘molar
tooth sign,’’ characterized by elongated superior cerebellar
peduncles, deepened interpeduncular fossa, and cerebellar ver-
mis hypoplasia. For each of these conditions, significant pheno-
typic variability hasbeenobserved evenbetweenmembers of the
same family, making clinical diagnosis a challenge.
Now that these conditions have been united by their under-
lying cell biology, we can begin to see commonalities between
individual syndromes (Figure 2A). For instance, low muscle
tone, cystic kidney disease, agenesis of the brain’s corpus
callosum, mental retardation, and hyperpnea/apnea are addi-
tional clinical features often present in ciliopathy patients. Indi-
viduals affected by BBS can have several clinical features
common to JBTS such as mental retardation, hypotonia, and
apnea. However, they also share other symptoms that are
usually not present in JBTS but are common to other ciliopathies,
such as polydactyly and retinal dystrophy (RD). Moreover, BBS
patients are usually obese, a unique trait that is absent among
the other ciliopathies.
The first few genes identified from positional cloning of human
or mouse phenotypes for what would eventually become the
ciliopathies initially did not point in an obvious way to the cilium
as the site of action. It was not until evidence began to accumu-
late that the encoded proteins localize specifically near the cilium
that the field was born (Ansley et al., 2003; Barr and Sternberg,
1999; Kim et al., 2004; Otto et al., 2003; Taulman et al., 2001).
Although the localization data is now incontrovertible, the func-
tions of the encoded proteins at the cilium for the most part still
remain a mystery, and some of the effects of these proteins donot seem to have direct relevance to ciliary function (Yen et al.,
2006). The question that emerges is how a single subcellular
organelle can mediate such diverse clinical features.
About 50 genes encoding predominantly ciliary-localized
proteins have now been identified that are mutated in these
partially overlapping syndromes (Figure 2B). In a series of posi-
tional cloning studies, each of these ciliopathy genes was initially
found as causative for a restricted phenotype. Surprisingly, in
most instances, this gene identification was followed by reports
of mutations in the same gene in a different ciliopathy category
(Baala et al., 2007a, 2007b; den Hollander et al., 2006). This
occurred with such regularity that the field began to wonder
whether any genotype-phenotype correlations would stand the
test of time. How could mutations in a single gene produce
such pleiotropic phenotypic effects in patients? Were these
observations exceptions to the rule of strict genotype-pheno-
type correlation, or were they the exception that proves the
rule of widespread phenotypic pleiotropy?
The Primary Cilium Network
The primary cilium is a hair-like, immotile cellular organelle
protruding from almost all eukaryotic cells, frequently described
as the cell’s ‘‘antenna’’ for transducing extracellular signals. For
the purposes of this Review, we focus exclusively on diseases
involving nonmotile cilia and do not include diseases like primary
cilia dyskinesia that involve motile cilia, as there is little pheno-
typic or genetic overlap. Cilia are generated during interphase
from the mother centriole by coalescence of vesicles at its distal
end that fuse with the plasma membrane. After this docking of
the mother centriole, the microtubule axoneme protrudes out
of the cell, concurrent with recruitment of a host of ciliary-
specific proteins. The basal body (i.e., the docked mother
centriole) possesses several specialized accessory structures
termed transition fibers, basal feet, and ciliary rootlets and is sur-
rounded by the pericentriolar matrix. But for many years, the
molecular determinants of these structures were unknown.
Recent work has begun to hint at the molecular architecture
of these anatomically defined structures. The 9+0 microtubuleCell 147, September 30, 2011 ª2011 Elsevier Inc. 71
Figure 2. Phenotypic and Interactome Diversity of the Ciliopathies Based upon Major Organ Involvement
(A) Disease is represented below by abbreviation, and involvement of major organ is listed above.
(B) Major ciliopathy diseases (color coded by severity) and gene mutated in each condition (red) linked by black bar, with more common causes showing thicker
lines.
(C) The same gene map, now indicating evidence for direct interaction between protein products. Protein interaction networks identified from published data,
demonstrating major clustering of interactions corresponding to disease networks. Note that genes causing a particular disorder tend to have products that
interact, although there are many genes without known connections. Note that genes such as CEP290 that can cause several different diseases should serve as
hubs but, to date, have few demonstrated physical interactions.
BBS, Bardet-Biedl syndrome; JBTS, Joubert syndrome; LCA, Leber congenital amaurosis; MKS, Meckel syndrome; NPHP, nephronophthisis; OFD,
Orofaciodigital syndrome; SLS, Senior Loken syndrome.arrangement of the axoneme emerges from the basal body in
a triplet configuration and shifts to a doublet configuration at
the ciliary transition zone (TZ). The Y-shaped microtubule exten-
sions that define the TZ require the Cep290 protein for their
formation in Chlamydamonas (Craige et al., 2010), although it is
not clear whether Cep290 constitutes or otherwise contributes
to these structures or whether this function is conserved in verte-72 Cell 147, September 30, 2011 ª2011 Elsevier Inc.brates. The location of the TZ marks the ciliary diffusion barrier:
a septin-2 cytoskeleton that separates the ciliary and cyto-
plasmic compartments (Hu et al., 2010). Attention has shifted
to the TZ as the site of action of proteins mutated in several
ciliopathies (Garcia-Gonzalo et al., 2011), but clear structure-
function relationships are still lacking. Protein synthesis and
vesicular transport do not occur inside cilia, so the assembly of
this organelle, its maintenance, and its function are totally
dependent upon an intraflagellar transport system by which
proteins track bidirectionally along the polarized microtubules
of the axoneme (Kozminski et al., 1993).
Although the involvement of primary cilia in human diseases is
now well established, many questions about its function remain.
The current paradigm describes the primary cilium as an organ-
elle for detecting and modulating the response to extracellular
signaling molecules and as a location for organizing their cyto-
plasmic effectors. It is well poised to mediate both effects, as
cilia typically protrude in a polarized fashion, which can help
the cell interpret the context of extracellular signals. Many
cellular receptors are localized to the primary cilium, and the
basal body is itself a signaling hub, probably serving as an effi-
cient transit point to transmit signals into the nucleus. In fact,
a number of transcription factors undergo processing within or
near the cilium prior to nuclear entry. Numerous critical develop-
mental signaling pathways have been directly linked to primary
cilia, such as Hedgehog (Hh), canonical and noncanonical Wnt,
and some forms of PDGF signaling, highlighting cilia’s role as
a signaling hub (Huangfu et al., 2003; Schneider et al., 2005;
Simons et al., 2005). In addition to the modulation of these
signaling pathways, primary cilia are essential for mechanical,
odor, and photo reception. The interpretation of the ciliopathies
as a unique group of disorders associatedwith defects in a single
organelle gave a new direction to the investigation of these
human diseases.
Proteomics Merges with Genomics
The marriage of proteomics with genomics in the area of ciliary
biology can be traced to an influential paper showing that the
RFX-type transcription factor DAF-19 is essential for assembly
of cilia in C. elegans sensory neurons and regulates several
genes encoding intraflagellar transport proteins (Swoboda
et al., 2000). The RFX transcription factor family emerged in cili-
ated proto-eukaryotes, but it was only later that the RFX genes
were co-opted to regulate expression of cilia-specific genes
based upon the presence of an X box in their promoter (Piasecki
et al., 2010). This work set the stage for a comparative genomics
approach to search for X-box-containing genes that were likely
to encode proteins relevant to primary cilia. Two follow-up
studies demonstrated the potential of this approach in identi-
fying important components of the primary cilium (Avidor-Reiss
et al., 2004; Li et al., 2004) and raised the idea of building a ciliary
protein database. The ciliome (Gherman et al., 2006; Inglis et al.,
2006) now consists of more than 3000 genes encoding proteins
either localized to cilia or essential for their assembly or function
(Arnaiz et al., 2009).
The ciliary proteome has already proved to be a powerful
resource, accelerating the identification of candidate human
ciliopathy genes by short-listing positional candidates. For
example, the cloning ofMKS1, BBS3, BBS5, and the BBSmodi-
fier MGC1203 was achieved by sequencing a reduced set of
candidate genes (Badano et al., 2006; Chiang et al., 2004;
Kytta¨la¨ et al., 2006; Li et al., 2004). Extending the idea of a ciliary
proteome to a ciliary ‘‘interactome’’ was the natural extension of
this work through the identification of proteins that physically
interact as part of specific complexes (Eley et al., 2008; Gordenet al., 2008). Through pair-wise testing of potential yeast two-
hybrid interactions (Otto et al., 2005) and identification of binding
partners by serial mass spectrometry (Nachury et al., 2007;
Sang et al., 2011), a number of discrete, functionally relevant
complexes have now emerged as the likely minimal disease-
causing modules (Figure 2C).
An important observation, which has stood the test of time, is
that the composition of these specific protein modules could
have been predicted based upon the phenotype observed in
patients. Specifically, the proteins from seven of the eight most
conserved genes mutated in BBS form a core complex termed
the BBSome (Nachury et al., 2007), found to play important roles
in ciliary protein and vesicular transport. Importantly, this
complex does not contain proteins encoded by other ciliopathy
diseases genes such as NPHP, JBTS, or MKS. This is perhaps
surprising considering that mutations in MKS genes can cause
BBS (Leitch et al., 2008). Three separate complexes containing
many of the proteins mutated in NPHP, JBTS, and MKS were
recently identified, and although their function is still under inves-
tigation, genes for two of the copurifying proteins, ATXN10 and
TCTN2, were found to be mutated in patients matching the
same ‘‘module’’ phenotype (Sang et al., 2011). In general, the
complexes also display specificity in subcellular localization
and function: the MKS/JBTS complex transduces hedgehog
signaling and localizes to the ciliary transition zone, whereas
the BBS complex forms a coat complex to target vesicles to
the cilium and localizes to ciliary membrane (Jin et al., 2010).
Proteins have nonredundant function within a given module
and do not associate or function in other modules.
This work has been further corroborated by analyzing a series
of C. elegans double mutants, which demonstrate worsened
synthetic phenotypes (i.e., functional interactions) only when
mutations occur in two different modules (Williams et al.,
2011), but not with two different mutations in the same module.
For instance, the B9 domain proteins of the MKS module func-
tionally interact with the NPHP module (Williams et al., 2008),
but not with most other genes in the MKS module. The conclu-
sion is that each module probably mediates partially separate
ciliary functions. Inactivating one component in a module is
probably sufficient to fully inactivate the module, so functional
interaction is only observed by inactivating a component in
a different module. Taken together, these examples show that
the availability of various disease proteomes in combination
with the explosion of currently available genomic and transcrip-
tomic data sets are driving forward biological network analysis in
human disease (Figure 3).
Genetic Complexity of Human Ciliopathies
Allelic Diversity
What can the study of the ciliopathies teach us about the future
direction of human genetic disease?Most obviously, that human
genetics will be a lot more complex than many of us would have
predicted. One obvious example is in the degree of multiple
allelism at particular genetic loci. Although some of the ciliopathy
genes are associated with only a single phenotypic class to date,
other gene mutations can result in phenotypes along the entire
ciliopathy clinical spectrum. For instance, mutations in CEP290
are reported in MKS, JBTS, NPHP, BBS, and LCA, spanningCell 147, September 30, 2011 ª2011 Elsevier Inc. 73
Figure 3. Discovery Pipeline for Mechanism
of Disease: Past and Future Paradigms
(A) Former strategy to identify disease mecha-
nisms, startingwith ascertainment of pedigrees for
linkage, disease mapping to a particular chromo-
somal locus, and candidate gene Sanger
sequencing. Once a mutant gene was identified,
animal models were created to understand the
mechanism.
(B) The future paradigm bypasses the need for
informative pedigrees and disease mapping,
instead going directly from patient ascertainment
to genome sequencing and then to variant identi-
fication and expanding to identification of modi-
fiers and mutational load. In parallel, patient-
specific disease modeling using human cells
coupled with protein interaction networks and
therapeutic drug screening can further uncover
disease mechanisms and help develop better
treatments.the full breadth of severity (Coppieters et al., 2010b), whereas
ARL13B mutations are restricted to patients with JBTS. For
ARL13B, it is not clear whether this gene is only capable of
causing a restricted phenotype or whether there are additional
mutations to be identified in other ciliopathy class disorders.
Current data would suggest the latter, as only hypomorphic
mutations in ARL13B gene were identified in humans, whereas
comparably more severe phenotypes were observed in mouse
and zebrafish (Caspary et al., 2007; Sun et al., 2004), suggesting
that the full spectrum of disease-causing alleles has not yet been
reported.
In the case of CEP290, despite the identification of over 100
unique disease-causing mutations, the ability to predict pheno-
type based upon genotype is extremely limited. The mechanism
underlying the different clinical outcomes of distinct mutations is
not always clear. One possibility might relate to the type of muta-
tions and their locations as predictors of phenotypic severity.
Though there are some types of mutations associated with
particular phenotypes, such as the c.2991+1655A/G variant
present in 21% of all LCA patients (den Hollander et al., 2006),
the exact same mutation can be seen in two different ciliopathy
classes (Coppieters et al., 2010b).74 Cell 147, September 30, 2011 ª2011 Elsevier Inc.There are other examples of pleiotropy
in the ciliopathies. NPHP1 mutations
are found in pure NPHP and NPHP with
RD (a combination known as SLS);
INPP5E mutations are found in JBTS as
well as BBS-like conditions. The case of
TMEM67 deserves special attention in
that mutations cause a broad range of
phenotypic combinations that comprise
renal cyst, liver fibrosis, central nervous
system malformations, retinal manifesta-
tions, and postaxial polydactyly. The
gene was first identified as both a cause
of MKS3 and the origin of the multiple
phenotypes of theWpk rat, which include
PKD, agenesis of the corpus callosum,
and hydrocephalus (Smith et al., 2006).Thereafter, more than 80 TMEM67 mutations were identified,
not only associated with MKS, but also with a peculiar form of
JBTS involving liver fibrosis and several renal and liver ciliopathy
syndromes in which missense mutations predominate (Brancati
et al., 2009; Iannicelli et al., 2010). Interestingly, the presence of
two truncating alleles or a missense mutation within exons 8–15
associates with the lethal MKS phenotypes, suggesting an
essential function of this region of the encoded protein that is
yet to be identified.
Modifiers
Whereas allelism offers one perspective with which to view
phenotypic pleiotropy, epistatic interactions and mutation load
offer another important perspective that deserves consideration.
Such reports are starting to emerge across the full spectrum of
human disease (Gu et al., 2009; Oprea et al., 2008) but are still
limited in number due to underpowered studies. Within the cilio-
pathies, recent studies of families with more than one affected
child and larger population screenings have highlighted an
important role of epistatic interactions, whereby the effect of
one gene modifies the phenotypic attributes of a different gene
(Leitch et al., 2008; Wiszniewski et al., 2011) (Figure 1C). For
this Review, we distinguish this from mutational load, whereby
the total genetic burden from accumulated deleterious variants
sums to produce the phenotype. It is now clear that the precise
disease manifestations and probably the timing of the appear-
ance of symptoms are subject to modification, which could
be in the form of stochastic, environmental, or genetic inputs.
The identification of genetically encoded modifiers offers the
potential to understand gene networks, improve prognostic
information, and identify targetable biochemical processes for
the development of therapeutic treatments.
Evidence that heritable factors in humans can alter the course
of ciliopathies came initially from an elegant series of experi-
ments involving the role of the MGC1203 gene (Badano et al.,
2006). The encoded protein, CCDC28B, contains a coiled-coil
domain and was identified in a yeast two-hybrid screen as
a BBS4-interacting protein. After demonstrating CCDC28B
interaction with several BBS proteins, the authors screened
a BBS cohort for potential MGC1203 mutations. Though none
of the patients carried a mutation known to cause BBS, a C-to-
T transition (C430T) in MGC1203 generated a splice defect in
about 10% of gene products. To test the involvement of C430T
as a potential modifier, they screened BBS and control cohorts
for this variant, finding that 6.2% of patients versus 1.4% of
controls carried the variant, representing an over-transmission
of the variant in transmission disequilibrium testing. The authors
reported three families with affected siblings carrying a homozy-
gous mutation on BBS1 in which the RD severity was associated
with the presence of the transition, suggesting that this variant
increases the likelihood of developing more severe BBS symp-
toms when associated with a known BBS mutation.
Since then, other examples of epistatic effects on RD associ-
ated with ciliopathies have emerged. Mutations in either AHI1 or
RPGRIP1L, which both encode ciliary-localized proteins, were
initially reported to cause JBTS. The AHI1 gene product physi-
cally interacts with nephrocystin-1 (Eley et al., 2008), the product
of the most commonly mutated NPHP gene, NPHP1. Because
more than 50% of patients with AHI1 mutations display RD/
LCA in addition to JBTS, investigators considered that AHI1
might be mutated in isolated RD/LCA. However, screening
a cohort of 176 mixed ancestry patients with LCA failed to
demonstrate any causative mutations, indicating that AHI1
mutations do not lead to isolated LCA in the absence diagnostic
JBTS features (Louie et al., 2010). However, Ahi1 mutant mice
predominantly displayed an LCA/RD phenotype, which was
more severe when synthetically combinedwith anNphp1mutant
allele, prompting investigation of epistatic interactions. Among
a cohort of 153 NPHP1 mutant patients, there was a significant
enrichment for a heterozygous c.C2488T change, leading to
a functional p.R830W substitution in those with RD. This trans-
lated into a 7.5-fold increase in RD in this population, which
represents one of the highest known risk alterations so far
described for any human disease. The c.C2488T allele therefore
significantly increases the risk of developing RD in the presence
of an NPHP1 mutation.
This association is not restricted to those with RD, as the same
c.C2488T allele was more commonly found in individuals with
NPHP1mutations displaying a more severe neurological pheno-
type (Tory et al., 2007). Nor are AHI1 variants solely restricted to
modifying NPHP1 phenotypes, as three unrelated patients withthe exact same CEP290 genotype (p.R1465X) presenting with
different clinical phenotypes showed variants in AHI1 that might
explain this discordance. AHI1 heterozygous transversions
(p.N811K and p.H758P) were found associated with greater
severity of nephrological and neurological phenotypes (Coppi-
eters et al., 2010a). Intriguingly the AHI1 variants in this case
had no effect on the presence of RD. Thus, these epistatic inter-
actions are both genotype specific and phenotype specific.
In studies that use model systems, it is possible to manipulate
gene structure or expression through a variety of techniques, but
investigation of geneticmodifiers in humans is limited to naturally
occurring variations. This might seem like a huge drawback
initially, but it has tremendous benefits in the long run because
large numbers of patients can be analyzed for the more common
variants. Several heterozygous variants have been reported in
RPGRIP1L in ciliopathy cohorts, and though their individual rarity
precluded further investigation, one remarkable exception, the
heterozygous p.A229T, is common enough to apply statistical
analysis. The RPGRIP1L protein interacts with RPGR, a ciliary
protein frequently mutated in RD, and this interaction is disrup-
ted in the presence of the p.A229T transversion (Khanna et al.,
2009). Individuals with this variant alone have normal vision, sug-
gesting that this heterozygous variant is silent in isolation.
However, it is enriched in ciliopathy patients with RD compared
to those without RD. There are probably many such gene-gene
interactions, but defining those of highest effect size and the
mechanisms by which these epistatic effects are manifested
will require new experimental strategies.
Mutational Load
Is it possible that such second site mutations might modify
not only the expressivity, but also the penetrance of disease?
BBS has long provided the classic example of oligogenicity
(Katsanis et al., 2001), representing the idea that second-site
mutations are necessary to produce an observable phenotype.
The demonstration that three mutant alleles at two different
loci were required for pathogenicity was among the first example
of oligogenic inheritance. In this example, investigators ob-
served that both affected and healthy children of an outbred
family carried two different nonsense mutations in BBS2
(p.Y24X and p.Q59X). In an effort to identify the differential
genetic trait that caused the disease in the affected sibling,
they identified a heterozygous nonsense potentially deleterious
sequence variant (PDSV) in BBS6 (Q147X) that was absent in
the healthy sibling, suggesting that the three different mutant
alleles were necessary to produce this phenotype. Subse-
quently, additional examples were described in which BBS
patients carried three mutant alleles in two different loci (Eichers
et al., 2004). However, in such examples, the segregation does
not exclude the possibility that two mutations in the same gene
are sufficient to cause disease in a different genetic background
(Mykytyn et al., 2003). Moreover, the lack of recurrence of such
combinations in BBS cohorts studied complicates the validation
of the oligogenic hypothesis.
Although oligogenic inheritance in BBS is still hotly contested,
several reports of possible oligogenic inheritance in other cilio-
pathies have emerged more recently (Hoefele et al., 2007;
Hopp et al., 2011), in which only single heterozygous PDSVs
are detected or in which patients with two deleterious mutationsCell 147, September 30, 2011 ª2011 Elsevier Inc. 75
in one gene also carry a heterozygous PDSV in a second gene.
The evidence for oligogenicity is somewhat tempered by the
natural limitations of the technology used to support the findings,
and whether such variants are functionally relevant and whether
they are overrepresented in patients compared with similarly
investigated controls is still a matter of debate. Nevertheless,
the observed phenotypic and genetic variability, together with
an apparent overabundance of PDSVs in ciliopathy genes,
have led to the general acceptance of a ‘‘mutational load’’
hypothesis. Defining the mutational load required for the mani-
festation of a given phenotypic combination or expressivity is
now the main challenging issue. One potential reason for opti-
mism is the emergence of next-generation sequencing, which
will allow genome-wide unbiased exploration of the mutational
load hypothesis. For instance, it would be fascinating to test
whether patients with ciliopathy phenotypes carry greater
burdens or particular patterns ofmutations in cilia-specific genes
compared with housekeeping genes on a genome-wide scale.
IPSCs, Cell-Based Screens, and Treatments
for Ciliopathies
What does the future of human genetics hold, and how can
disorders like the ciliopathies benefit from new technological
advances? Whole-genome sequencing (WGS) and whole-
exome sequencing (WES) are clearly the breakthroughs most
likely to impact the study ofMendelian disorders like ciliopathies.
The exons, accounting for 1% of the genome, harbor most
disease-causing mutations of high-effect size; therefore, WES
is a reasonable approach for finding novel disease-causing
genes. This is evident by the abundance of novel disease-
causing genes identified in recent years. The limitations of
WES can be overcome with WGS—with its ability to identify
not just variants in coding regions of the genes, but also variants
in introns, untranslated regions, and noncoding RNAs, such
as the recent discovery of mutations in the U4atac shRNA in
microcephalic osteodysplastic primordial dwarfism type I (Edery
et al., 2011; He et al., 2011). Additionally, with genome-wide
approaches, these data sets offer the possibility to directly test
the mutational load hypothesis and identify a host of epistatic
modifiers. At this point, we still require better bioinformatic tools
to predict resultant human phenotypes, but this technology is
already greatly benefiting the field of human genetics, with an
explosion in the number of newly discovered human disease
genes. The ciliopathies are no exception (Gilissen et al., 2010;
Hopp et al., 2011).
Combining these genetic discoveries with proteomic research
is another huge area for the future as molecular geneticists take
advantage of the explosion of new human disease genes. Iden-
tifying functional complexes, modules, and genetic pathways
through the identification of protein-binding partners and animal
modeling will yield more robust platforms fromwhich to consider
therapeutics. An example is in PKD, one of the most common
Mendelian diseases. Based upon the knowledge of similarities
in phenotype between PKD and tuberous sclerosis complex
(TSC), investigators wondered whether there was a possible
functional connection. The two genes mutated in TSC are
involved in the mTOR pathway, and some symptoms are treat-
able with mTOR inhibitors like rapamycin. Investigators hypoth-76 Cell 147, September 30, 2011 ª2011 Elsevier Inc.esized that PKD1 and tuberin (one of the genes mutated in TSC)
might interact. After confirming this hypothesis, they tested
whether, like TSC, PKD might be abrogated by mTOR inhibitors.
Strikingly, rapamycin results in a significant reversal of renal
cystogenesis in two different mouse models (Shillingford et al.,
2006), and these findings led to a clinical trial in humans. More
recent work hints at the possibility that mTOR inhibitors may
benefit other ciliopathy conditions (Tobin and Beales, 2008).
Although the human trials were not successful and will need to
be repeated with different endpoints, the story exemplifies the
streamlining of approaches as investigators move from human
disease genes to new treatments.
Because animal models can frequently be significantly
different than their human counterparts in terms of organ speci-
ficity and severity, they have been of limited benefit in directly
exploring disease pathogenesis. For instance, both published
mouse models for the most commonly mutated gene in human
NPHP, NPHP1, shows no detectable kidney phenotype. This
could be a result of functional differences in the kidney in humans
versus mice, differences in the types of mutations, or differences
in the genetic background. Although NPHP1 mutant mice have
some evidence of ciliopathy-like features, including aberrant
spermmaturation and a background-dependent genetic interac-
tion with AHI1 in RD (Jiang et al., 2009; Jiang et al., 2008; Louie
et al., 2010), in general, the use of animal models of human
disease often requires careful assessment of relevance.
As inmany other diseases, investigators that continue to return
to patients and patient-derived samples for clues to patho-
genesis are more apt to make disease-relevant discoveries.
Induced pluripotent stem cells (IPSCs) offer such an opportunity,
especially for diseases like ciliopathies, in which the genetic
background is probably critical for phenotypic expressivity. For
this reason, it might be preferable to work with a patient sample
carrying a known disease-causing mutation in the disease-
causing genetic background rather than a sample from a
knockout mouse, in which the species or the species’ genetic
background may not be appropriate for full expressivity. IPSCs
and other cellular reprogramming strategies offer an opportunity
to make discoveries in disease-relevant cells. For example,
a recent application of the spheroid cellular assay to probemech-
anistic insights of kidney cysts (Otto et al., 2010) might greatly
benefit from the use of patient-derived cells.
Functional genomic cell-based screens also offer a comple-
mentary approach to the study of human disease by leap-
frogging past animal models in the identification of potential
treatment-relevant targets. In the past year, a number of such
cell-based high-throughput or high-content screening systems
to identify genes required for cilium assembly and maintenance
or signaling pathways known to depend upon the cilium have
emerged. By combining stable isotope labeling with amino acids
in cell culture (SILAC) with BAC transgenesis in human cells, a list
of 135 new centriolar components that are specific to either the
mother or daughter centriole were identified (Jakobsen et al.,
2011). Given the important coordination of centriole function
with ciliogenesis, this list is likely to lead to many new functional
discoveries in the future. Genome-wide RNAi screening in cells
has identified the multitasking kinase Stk11 (a.k.a Lkb1) as
a key factor in cilium stability and an integrator of Shh and Wnt
signals in cells, two key pathways modulated by the cilium
(Jacob et al., 2011). Finally, two recent papers established the
genetic requirements of cilium assembly and length in mamma-
lian cells, highlighting the important contribution of the actin
cytoskeleton and showing that it is possible to uncouple ciliary
cargo transport from cilia formation in vertebrates (Kim et al.,
2010; Lai et al., 2011).
Rapidly evolving sequencing methods combined with the
underlying growth of informatic algorithms can provide the
power to uncover both new causes as well as new potential
treatments in human disease. Using the relatively simple
example of the ciliopathies, we can see how the paradigm is
shifting in experimental biology to one that is less reliant on the
pure study of animalmodels, in favor of using humans as amodel
to study human disease. Further integration of these new
approaches has the potential to yield improved diagnosis and
opens the window for new therapies across the field of genetics.
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